Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to …

Jul 27, 2023 · Two companies that are investing big money in weight-loss treatments are Eli Lilly (LLY-0.19%) and Novo Nordisk (NVO 0.32%). Shares of both companies are up more than …

CouponFollow Extension

19%
OFF

Eli Lilly Vs. Novo Nordisk: What's The Better Weight-Loss Stock To …

3 weeks from now

Jul 27, 2023 · Two companies that are investing big money in weight-loss treatments are Eli Lilly (LLY-0.19%) and Novo Nordisk (NVO 0.32%). Shares of both companies are up more than …

fool.com

77%
OFF

Better Buy: Novo Nordisk Vs. Eli Lilly | The Motley Fool

3 weeks from now

While Ozemipc is the brand name on everyone's lips when they talk about weight loss, it's only approved to control blood sugar and reduce the risk of heart attacks for patients with type 2 diabetes. Nevertheless, Ozempic sales soared 77% last year to $8.8 billion with help from off-labelweight-loss prescriptions as well as diabetes patients. Invest...

fool.com

6%
OFF

Eli Lilly Vs Novo Nordisk: A Recent Study Suggests This Company …

3 weeks from now

Aug 3, 2024 · Last year, Eli Lilly reported that in an 84-week study, patients were able to lose up to 26.6% of their body weight, on average, when using the drug. With semaglutide, patients …

yahoo.com

$44
OFF

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend …

3 weeks from now

Dec 20, 2024 · The two leading weight-loss drugs today are Wegovy from Novo Nordisk and Zepbound from Eli Lilly. Together, they are expected to generate about $44.6 billion in sales in …

investors.com

13%
OFF

Lilly And Novo Went Head-to-Head Over Weight-Loss Drugs In …

3 weeks from now

Despite ever-increasing sales, Eli Lilly stock is down 13% in the fourth quarter, while Novo’s American depositary receipts, or ADRs, are down 28%. Over the year, the difference is more …

msn.com

$130
OFF

Elon Musk Weighs In On Weight-Loss Drug Stocks. Is LLY… - Inkl

3 weeks from now

2 days ago · LLY vs. NVO: Which Stock Is a Better Buy? Both Eli Lilly and Novo Nordisk are poised to capitalize on the obesity drug market, projected to reach $130 billion by the decade’s …

inkl.com

$100
OFF

Eli Lilly Vs Novo Nordisk: A Recent Study Suggests This Company …

3 weeks from now

Eli Lilly appears to have the more effective weight loss drugs in its portfolio. But with a massive market for anti-obesity drugs that could top $100 billion, it may not mean that Novo Nordisk is ...

msn.com

25%
OFF

Eli Lilly Is The New Obesity Treatment King - WSJ

3 weeks from now

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments. ... falling short of the 25% weight loss Novo Nordisk had expected. Additionally, the ...

wsj.com

14%
OFF

Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss …

3 weeks from now

Dec 26, 2024 · NVO, LLY Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the last five years.

benzinga.com

$130
OFF

Elon Musk Weighs In On Weight-Loss Drug Stocks. Is LLY Or NVO A …

3 weeks from now

LLY vs. NVO: Which Stock Is a Better Buy? Both Eli Lilly and Novo Nordisk are poised to capitalize on the obesity drug market, projected to reach $130 billion by the decade’s end, …

msn.com

79%
OFF

Better Buy Now: Novo Nordisk Vs. Eli Lilly | The Motley Fool

3 weeks from now

Nov 13, 2023 · On Nov. 8, the active ingredient in Eli Lilly's (LLY 0.79%) type 2 diabetes treatment Mounjaro earned approval from the Food and Drug Administration (FDA) for chronic weight …

fool.com

32%
OFF

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, Or Viking ...

3 weeks from now

Mar 26, 2024 · The commercial success of Novo Nordisk's (NVO 0.32%) and Eli Lilly's (LLY-0.19%) new weight-loss drugs prove it. These two big biopharma companies probably won't …

fool.com

34%
OFF

Why Novo Nordisk Stock Got Destroyed Today, But Eli Lilly And …

3 weeks from now

Dec 20, 2024 · Bad news for Novo Nordisk (NVO 0.34%) Friday was good news for Eli Lilly (LLY-0.24%) and Viking Therapeutics (VKTX 1.18%), its two main rivals in the field of weight loss …

fool.com

24%
OFF

Is Eli Lilly Stock A Buy? - The Motley Fool

3 weeks from now

6 days ago · Reports indicate he was actually taking Eli Lilly's (LLY-0.24%) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its …

fool.com

FAQs about Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to … Coupon?

Should you buy Eli Lilly vs Novo Nordisk?

Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug was originally published by The Motley Fool These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. ...

Does Novo Nordisk have a lead on Lilly in GLP-1 market share?

Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, research suggests that GLP-1 drugs have applications outside of weight loss. ...

Is Eli Lilly a good stock to buy right now?

This recent news, while promising, doesn't necessarily make Eli Lilly a better stock to buy right now. Both of these stocks are good long-term investments. Shares of Novo Nordisk trade at 44 times trailing earnings, versus more than 110 times earnings for Eli Lilly, which makes Novo Nordisk stock a more attractive investment right now. ...

Is Lilly a good investment over Novo Nordisk?

I see Lilly as the superior investment over Novo Nordisk -- and frankly, I don't think it's even close. While I see the recent declines in Novo stock as a prime example of overblown panic selling, Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. ...

Will Eli Lilly & Novo Nordisk capitalize on the obesity drug market?

Both Eli Lilly and Novo Nordisk are poised to capitalize on the obesity drug market, projected to reach $130 billion by the decade’s end, according to Goldman Sachs Research. While Novo faces short-term challenges like the CagriSema trial results, its valuation and expansion efforts offer potential. ...

Will Eli Lilly & Novo Nordisk diverge in 2024?

The future market for GLP-1s is almost certainly enormous, and will benefit those with weight-loss drugs on the market. But it’s unlikely to be all smooth sailing, and the divergence of Eli Lilly and Novo Nordisk in 2024, and in the fourth quarter in particular, is a clear sign of that. ...